← Back to headlines
argenx announces positive results from ALKIVIA trial for autoimmune myositis
argenx has reported positive topline results from its Phase 3 ALKIVIA trial, evaluating efgartigimod for the treatment of autoimmune myositis.
17 Aug, 05:00 — 17 Aug, 05:00
Related Stories
Study Reveals Elderly More Vulnerable to Extreme Heat Than Previously Thought
29m ago
Nollywood Actor Ogogo Hassan's Daughters Seek Help for Father's Stage 4 Cancer
3h ago
West Nile Fever Cases and Fatalities Reported in Serbia and North Macedonia
8h ago
Metro Manila Inundated by Heavy Monsoon Rains
10h ago